Literature DB >> 8902272

Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis.

M Bourdi1, W Chen, R M Peter, J L Martin, J T Buters, S D Nelson, L R Pohl.   

Abstract

Autoantibodies against specific human cytochrome P450s have been found in the sera of patients suffering from a variety of diseases, including those caused by drugs. In the cases of tienilic acid- and dihydralazine-induced hepatitis, patients have serum autoantibodies directed against cytochromes P450 2C9 and P450 1A2, respectively. In the present study, we have found that 25 of 56 (45%) patients diagnosed with halothane hepatitis have autoantibodies that react with human cytochrome P450 2E1 that was purified from a baculovirus expression system. The autoantibodies inhibited the activity of cytochrome P450 2E1 and appeared to be directed against mainly conformational epitopes. In addition, because cytochrome P450 2E1 became trifluoroacetylated when it oxidatively metabolized halothane, it is possible that the covalently altered form of cytochrome P450 2E1 may be able to bypass the immunologic tolerance that normally exists against cytochrome P450 2E1. A similar mechanism may explain the formation of autoantibodies that have been found against other cellular targets of the reactive trifluoroacetyl chloride metabolite of halothane.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8902272     DOI: 10.1021/tx960083q

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  28 in total

Review 1.  Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update.

Authors:  E Boitier; P Beaune
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  Oxidative stress and antioxidants in hepatic pathogenesis.

Authors:  Hye-Lin Ha; Hye-Jun Shin; Mark A Feitelson; Dae-Yeul Yu
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

3.  Evidence for cellular protein covalent binding derived from styrene metabolite.

Authors:  Wei Yuan; Hua Jin; Jou-Ku Chung; Jiang Zheng
Journal:  Chem Biol Interact       Date:  2010-05-12       Impact factor: 5.192

Review 4.  Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame.

Authors:  Sung-Mi Kim; YongQiang Wang; Noushin Nabavi; Yi Liu; Maria Almira Correia
Journal:  Drug Metab Rev       Date:  2016-06-20       Impact factor: 4.518

5.  CYP2E1 immunoglobulin G4 subclass antibodies after desflurane anesthesia.

Authors:  Chrysanthi Batistaki; George Michalopoulos; Paraskevi Matsota; Tzortzis Nomikos; Konstantinos Kalimeris; Maria Riga; Maria Nakou; Georgia Kostopanagiotou
Journal:  World J Hepatol       Date:  2014-05-27

6.  Trifluoroacetylated IgG4 antibodies in a child with idiosyncratic acute liver failure after first exposure to halothane.

Authors:  Christine Nguyen; Noel R Rose; Dolores B Njoku
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-08       Impact factor: 2.839

7.  Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury.

Authors:  Dolores B Njoku; Zhaoxia Li; Nicole D Washington; Jenelle L Mellerson; Monica V Talor; Rajni Sharma; Noel R Rose
Journal:  Eur J Immunol       Date:  2009-06       Impact factor: 5.532

8.  Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure.

Authors:  Imir G Metushi; Corron Sanders; William M Lee; Jack Uetrecht
Journal:  Hepatology       Date:  2014-01-27       Impact factor: 17.425

Review 9.  CYP2E1 and oxidative liver injury by alcohol.

Authors:  Yongke Lu; Arthur I Cederbaum
Journal:  Free Radic Biol Med       Date:  2007-11-17       Impact factor: 7.376

10.  IP-10 protects while MIP-2 promotes experimental anesthetic hapten - induced hepatitis.

Authors:  Dolores B Njoku; Zhaoxia Li; Jenelle L Mellerson; Rajni Sharma; Monica V Talor; Nicole Barat; Noel R Rose
Journal:  J Autoimmun       Date:  2009-01-07       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.